dexamethasone intravitreal implant (SMO-IVT1) / SANGMYUNG innovation - LARVOL DELTA

A prospective, multicenter clinical study comparing the efficacy of dexamethasone intravitreal implantation combined with aflibercept versus aflibercept monotherapy in the treatment of diabetic macular edema. (ChiCTR) - P4 | N=114 | Not yet recruiting | Sponsor: Shanghai General Hospital; Shanghai General Hospital

New P4 trial • Diabetic Macular Edema • Ophthalmology

BETTIS-1: EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - P1/2 | N=75 | Active, not recruiting | Sponsor: Eclipse Life Sciences, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Oct 2026

Enrollment closed • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

Correlation between the optical density ratio of subretinal fluid in OCT images and visual outcome in eyes with diabetic MacularEdema. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "In DME patients with SRD, patients with a lower baseline subretinal fluid ODR had better visual quality recovery after the anti-VEGF drug or steroid hormone treatment, identifying the optical density in subretinal fluid as a clinically relevant biomarker in diabetic macularedema."

Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant (clinicaltrials.gov) - P=N/A | N=236 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Aug 2026 | Trial primary completion date: Dec 2026 ➔ Aug 2026

Trial completion • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

Dexamethasone intravitreal implant (Ozurdex) monotherapy for uveitic macular edema secondary to non-infectious uveitis: a single-center retrospective cohort study. (PubMed, Int Ophthalmol) - "In this selected real-world cohort, dexamethasone implant monotherapy was associated with significant anatomical improvement and early functional improvement, with high 12 month follow-up completeness. The initial implant provided a clinically useful but time-limited treatment effect, and repeat implantation was required in a subset of eyes. These findings support dexamethasone implant as a local treatment strategy for selected patients with uveitic macular edema while emphasizing the need for monitoring of ocular steroid-related adverse effects and individualized long-term inflammatory management."

Journal • Monotherapy • Retrospective data • Review • Cataract • Glaucoma • Immunology • Inflammation • Inflammatory Arthritis • Macular Edema • Ocular Inflammation • Ophthalmology • Psoriatic Arthritis • Rheumatology • Sarcoidosis • Seronegative Spondyloarthropathies • Uveitis

Dexamethasone Implant in Epiretinal Membrane Surgery: A Clinically Oriented Narrative Review of Current Evidence, Biomarkers and Patient Selection. (PubMed, J Clin Med) - "Moreover, while current evidence suggests that DEX implantation may accelerate anatomical recovery and improve postoperative inflammatory control in selected patients, long-term functional superiority over PPV alone, including sustained BCVA improvement and patient-reported visual outcomes such as metamorphopsia, remains unproven. Larger prospective randomized studies are needed to better define optimal patient selection and treatment timing."

Biomarker • Journal • Review • Cataract • Inflammation • Macular Edema • Ophthalmology • Retinal Disorders

Twelve‑month Response and Safety of Intravitreal Dexamethasone Implant in Treatment‑Naïve and Recalcitrant Cystoid Macular Edema Secondary to Branch Retinal Vein Occlusion (TREAT-BRVO Study). (PubMed, Clin Ophthalmol) - "To compare anatomical and visual outcomes following dexamethasone intravitreal implant (Ozurdex) in treatment-naive versus recalcitrant cystoid macular edema (CME) secondary to branch retinal vein occlusion (BRVO). Intravitreal dexamethasone implant was associated with significant anatomical and functional improvements in both treatment-naïve and anti-VEGF refractory BRVO-related CME. While no statistically significant differences were identified between the groups, adequately powered prospective studies are required to determine whether treatment outcomes differ according to prior anti-VEGF exposure."

Journal • Cataract • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Intraocular Pressure Elevation After Suprachoroidal Triamcinolone Acetonide in Noninfectious Uveitis: An IRIS® Registry Study. (PubMed, Ophthalmol Glaucoma) - "In this large real-world cohort of patients with NIU, both SCS-TA and DEX were associated with higher risks of clinically significant IOP elevation compared with systemic therapy controls, with broadly similar incidence between the two CS delivery approaches. Although IOP-lowering medications were more frequently required, the overall incidence of glaucoma surgery remained low."

Journal • Cardiovascular • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

Study of Clinical Observation and Mechanism of Conbercept Combined with Dexamethasone Intravitreal Implant in the Treatment of Refractory Macular Edema (ChiCTR) - P4 | N=60 | Recruiting | Sponsor: Shenzhen University General Hospital; Shenzhen University General Hospital

New P4 trial • Macular Edema • Ophthalmology